What are the side effects of cimepilimab?

Cemiplimab (Cemiplimab) is a monoclonal antibody targeting programmed death receptor-1 (PD-1). It is mainly used to treat cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC). As an immune checkpoint inhibitor, cimepilimab exerts anti-tumor effects by enhancing the body's immune system's ability to recognize and attack tumors. However, the use of cimepilimab is also associated with certain side effects, many of which are related to overactivation of the immune system.

The side effects of cimepilimab can be roughly divided into two categories: mild and severe. Relatively common minor side effects include fatigue, rash, and loss of appetite. These side effects are usually relatively easy to manage and can be effectively alleviated with appropriate medication or lifestyle modifications.

More serious side effects include immune-related adverse reactions. For example, hypothyroidism and hyperthyroidism are common endocrine system side effects. Hypothyroidism may cause patients to experience symptoms such as fatigue, weight gain, depression, and dry skin, while hyperthyroidism may cause weight loss, heart palpitations, anxiety, etc. Monitoring thyroid function and administering hormone replacement or antithyroid medications when necessary are critical in managing these side effects.

Pneumonitis is also an important side effect of cimepilimab treatment, manifesting as shortness of breath, cough and other symptoms. If you notice these symptoms, you should seek medical advice promptly for evaluation and treatment to prevent the condition from getting worse. Studies have shown that when cimepilimab is used in combination with platinum-based chemotherapy, the incidence of certain side effects, such as thyroid dysfunction and pneumonia, may be increased. Therefore, patients need to carefully monitor their health status when using combined treatment options.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4347ae1f-d397-4f18-8b70-03897e1c054a